NEOGENOMICS INC
For the period ended Dec 31, 2023. Filed Feb 20, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Feb 20, 2024
NEO$16.96-3.6%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 8. Financial Statements and Supplementary Data
| Table of Contents | NEOGENOMICS, INC. |
|---|
INDEX TO CONSOLIDATED FINANCIAL STATEMENTS
| Page | |
|---|---|
| Report of Independent Registered Public Accounting Firm – Deloitte & Touche LLP (PCAOB ID: 34) | 54 |
| Consolidated Balance Sheets as of December 31, 2023 and 2022 | 56 |
| Consolidated Statements of Operations for the years ended December 31, 2023, 2022 and 2021 | 57 |
| Consolidated Statements of Comprehensive (Loss) Income for the years ended December 31, 2023, 2022 and 2021 | 58 |
| Consolidated Statements of Stockholders’ Equity for the years ended December 31, 2023, 2022 and 2021 | 59 |
| Consolidated Statements of Cash Flows for the years ended December 31, 2023, 2022 and 2021 | 60 |
| Notes to Consolidated Financial Statements | 61 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.